Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Stanley Black & Decker, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.2 (market cap $39.89B), while Stanley Black & Decker, Inc. trades at $87.46 (market cap $13.71B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.9× Stanley Black & Decker, Inc.'s market cap, and Stanley Black & Decker, Inc. pays a 3.76% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | SWK | |
|---|---|---|
Market Cap | $39.89B | $13.71B |
Sector | Health | — |
52-Week High | $491.22 | $94.12 |
52-Week Low | $278.09 | $62.12 |
Enterprise Value | $38.15B | $19.88B |
Dividend Yield | — | 3.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Stanley Black & Decker (SWK) trades at $88.22, up 1.61% with a bullish technical signal and consistent earnings beats. The stock shows strong valuation metrics with P/S of 0.88 and P/B of 1.53, while profitability remains modest with 2.44% net margin. Recent corporate actions include a $0.83 dividend payment, and cash flow trends indicate operational stability despite slight net outflows.
SWK presents a mixed outlook with positive earnings momentum and aerospace/automotive demand offset by Tools & Outdoor segment weakness and elevated debt. Analyst consensus leans neutral (51% Hold) with $82.75 price target below current levels. Key risks include consumer sentiment pressures and high debt load, though cost-saving initiatives support turnaround potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
